We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$540K
Cap. Flow
+$13.4M
Cap. Flow %
3.48%
Top 10 Hldgs %
70.32%
Holding
34
New
1
Increased
10
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$22M
2
NTLA icon
Intellia Therapeutics
NTLA
+$4.6M
3
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$3.46M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.21M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.81M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$12.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$7.68M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$3.53M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$2.19M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$1.45M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$78.2M 20.33%
7,648,268
– –
PRVB
2
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$28.3M 7.35%
1,173,809
+275,326
+31% +$3.46M
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$25.4M 6.61%
1,045,691
-13,997
-1% -$306K
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$23.8M 6.17%
1,745,943
– –
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
$22.5M 5.85%
1,192,281
-94,154
-7% -$2.19M
NTLA icon
6
Intellia Therapeutics
NTLA
$1.8B
$21.3M 5.54%
572,459
+117,221
+26% +$4.6M
RLAY icon
7
Relay Therapeutics
RLAY
$4.11B
$20.2M 5.24%
+1,225,634
New +$22M
GERN icon
8
Geron
GERN
$970M
$18.2M 4.74%
8,401,565
-65,416
-0.8% -$186K
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$16.5M 4.3%
176,874
-17,307
-9% -$1.02M
RPTX
10
DELISTED
Repare Therapeutics
RPTX
$16.1M 4.19%
1,639,849
– –
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.63B
$16M 4.15%
2,614,977
+465,427
+22% +$3.21M
RGNX icon
12
Regenxbio
RGNX
$638M
$11.7M 3.03%
617,671
-3,701
-0.6% -$81.9K
VERV
13
DELISTED
Verve Therapeutics
VERV
$11.6M 3.01%
803,501
-5,160
-0.6% -$101K
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.3B
$8.73M 2.27%
36,038
+9,265
+35% +$2.52M
TVTX icon
15
Travere Therapeutics
TVTX
$6.19B
$7.05M 1.83%
313,642
+31,931
+11% +$679K
QURE icon
16
uniQure
QURE
$3.38B
$7.01M 1.82%
348,224
-591,742
-63% -$12.4M
INSM icon
17
Insmed
INSM
$25.9B
$6.81M 1.77%
399,192
-11,271
-3% -$219K
HOWL icon
18
Werewolf Therapeutics
HOWL
$45.8M
$6.21M 1.61%
2,388,011
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$9B
$5.79M 1.5%
360,392
-11,247
-3% -$208K
RVMD icon
20
Revolution Medicines
RVMD
$44.6B
$5.35M 1.39%
247,022
+97,979
+66% +$2.41M
TCRR
21
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.06M 1.31%
3,370,982
– –
KDNY
22
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.58M 1.19%
197,806
+117,806
+147% +$2.81M
AXSM icon
23
Axsome Therapeutics
AXSM
$10.4B
$4.34M 1.13%
70,402
+18,427
+35% +$1.21M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$4.31M 1.12%
388,292
-12,118
-3% -$149K
ARQT icon
25
Arcutis Biotherapeutics
ARQT
$2.99B
$2.8M 0.73%
254,137
-7,932
-3% -$115K
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2023 Portfolio in Review

As of Q1 2023, MPM BioImpact held 34 positions worth $385M, down 0.14% from $385M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

MPM BioImpact deployed $13.4M of net new capital in Q1 2023, opening 1 new position and adding to 10 existing holdings. Its largest new stake was Relay Therapeutics: 1,225,634 shares worth $20.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $12.4M trimmed.

  • MPM BioImpact's largest Q1 2023 buy was Relay Therapeutics: 1,225,634 shares worth $20.2M.
  • MPM BioImpact added most to Intellia Therapeutics in Q1 2023, an estimated $4.6M increase.
  • MPM BioImpact's biggest Q1 2023 reduction was uniQure, cutting an estimated $12.4M.
  • MPM BioImpact fully exited Harmony Biosciences in Q1 2023, selling an estimated $7.68M.
  • MPM BioImpact's ten largest holdings make up 70% of its $385M portfolio in Q1 2023.
  • MPM BioImpact opened 1 new position and closed 3 in Q1 2023.
  • MPM BioImpact's portfolio value fell 0.14% quarter-over-quarter to $385M.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.